{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:27:41Z","timestamp":1794536861929,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Biogen Japan","award":["Award Number: N\/A"],"award-info":[{"award-number":["Award Number: N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Nusinersen therapy for spinal muscular atrophy (SMA) provides significant functional improvement when initiated pre-symptomatically or early in life. However, challenges remain in diverse populations with longer disease duration. In Japan, innovative cybernic therapy with the Hybrid Assistive Limb (HAL) is gaining traction in treating neuromuscular diseases. This observational study investigated whether combining HAL therapy with nusinersen and conventional physiotherapy yields functional improvements in SMA, irrespective of disease duration or age. Functional improvement indicators included the Hammersmith Functional Motor Scale-Expanded (HFMSE) and Revised Upper Limb Module (RULM) scores, and the 2-minute walk test (2MWT), measured 15 months post-nusinersen initiation. A cohort analysis of a selected case series was conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twelve patients with SMA type 2 or 3 who met the criteria of being able to walk with a hoist and began nusinersen treatment\u2009&gt;\u200940 months post-disease onset were selected for longitudinal clinical assessment. Cohort 1 (<jats:italic>n<\/jats:italic>\u2009=\u20095, mean age 36.0 years) underwent HAL therapy, while Cohort 2 (<jats:italic>n<\/jats:italic>\u2009=\u20097, 24.6 years) did not. Baseline characteristics, except mean age, were similar across cohorts. In Cohort 1, the period from baseline (nusinersen initiation) to HAL therapy ranged from 0 to 8.8 months. HFMSE scores improved in both cohorts at 15 months; the least squares mean (LSM) change from baseline (95% confidence interval [CI]) was 4.7 points (2.2, 7.3) in Cohort 1 and 2.9 points (0.7, 5.1) in Cohort 2. Clinically meaningful improvement of 3.0 points in HFSME was exceeded by four of five patients in Cohort 1 and three of seven in Cohort 2. The LSM change from baseline in RULM was 2.2 points (95% CI 1.0, 3.3) in Cohort 1, exceeding the minimal clinically important difference of 0.5\u20131.0 points, but remained unchanged in Cohort 2 due to ceiling effects (\u2212\u20090.2; \u22121.5, 1.2; <jats:italic>p<\/jats:italic>\u2009=\u20090.016). The LSM change from baseline in the 2MWT had improved in Cohort 1 (34.57\u00a0m; 95% CI 4.57, 64.57), but not in Cohort 2 (\u2212\u20093.86; \u221237.75, 30.03).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In patients with SMA type 2 and 3, clinically meaningful improvements in multiple indicators were observed when HAL was combined with nusinersen, even when treatment commenced many years after disease onset.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration<\/jats:title>\n            <jats:p>jRCT1090220400 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCT1090220400\" ext-link-type=\"uri\">https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCT1090220400<\/jats:ext-link>).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03681-9","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:57:24Z","timestamp":1745409444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Enhancing the effects of nusinersen with cybernic treatment using Hybrid Assistive Limb (HAL) in spinal muscular atrophy: a real-world case series and exploratory cohort analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-6619","authenticated-orcid":false,"given":"Takashi","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Nakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"3681_CR1","volume-title":"Spinal muscular atrophy: classification, diagnosis, background, molecular mechanism and development of therapeutics","author":"FT Farooq","year":"2013","unstructured":"Farooq FT, Holcik M, MacKenzie A. In: Kishore U, editor. Spinal muscular atrophy: classification, diagnosis, background, molecular mechanism and development of therapeutics. Neurodegenerative Diseases: InTechOpen; 2013."},{"issue":"1","key":"3681_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8(1):52.","journal-title":"Nat Rev Dis Primers"},{"key":"3681_CR3","unstructured":"Moultrie F, Chiverton L, Hatami I, Lilien C, Servais L. Pushing the boundaries: future directions in the management of spinal muscular atrophy. Trends Mol Med [Internet]. 2025 Jan 9:[S1471-4914(24)00339-3 pp.]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39794178"},{"issue":"1","key":"3681_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"4","key":"3681_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","volume":"119","author":"B Wirth","year":"2006","unstructured":"Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119(4):422\u20138.","journal-title":"Hum Genet"},{"issue":"3","key":"3681_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, March F, Vencesl\u00e1 A, Rodr\u00edguez-\u00c1lvarez FJ, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3681_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.braindev.2021.08.002","volume":"44","author":"M Ito","year":"2022","unstructured":"Ito M, Yamauchi A, Urano M, Kato T, Matsuo M, Nakashima K, et al. Epidemiological investigation of spinal muscular atrophy in Japan. Brain Dev. 2022;44(1):2\u201316.","journal-title":"Brain Dev"},{"key":"3681_CR8","unstructured":"Chapter 2. Developmental aspects and pathological findings in spinal muscular atrophy. In: Sumner CJ, Paushkin S, Chien-Ping K, editors. Spinal muscular atrophy disease mechanisms and therapy. 1st ed. Elsevier; 2016:506."},{"issue":"2","key":"3681_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.nmd.2020.12.007","volume":"31","author":"RI Wadman","year":"2021","unstructured":"Wadman RI, De Amicis R, Brusa C, Battezzati A, Bertoli S, Davis T, et al. Feeding difficulties in children and adolescents with spinal muscular atrophy type 2. Neuromuscul Disord. 2021;31(2):101\u201312.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"3681_CR10","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1212\/WNL.0000000000011051","volume":"96","author":"F Trucco","year":"2021","unstructured":"Trucco F, Ridout D, Scoto M, Coratti G, Main ML, Muni Lofra R, et al. Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study. Neurology. 2021;96(4):e587\u201399.","journal-title":"Neurology"},{"issue":"15","key":"3681_CR11","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24(15):1634\u201344.","journal-title":"Genes Dev"},{"issue":"15","key":"3681_CR12","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, et al. Discovery of Risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317.","journal-title":"J Med Chem"},{"issue":"18","key":"3681_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"7","key":"3681_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"3681_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","volume":"35","author":"SM Hoy","year":"2021","unstructured":"Hoy SM. Nusinersen: a review in 5q spinal muscular atrophy. CNS Drugs. 2021;35(12):1317\u201328.","journal-title":"CNS Drugs"},{"issue":"7","key":"3681_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40263-018-0545-1","volume":"32","author":"SM Hoy","year":"2018","unstructured":"Hoy SM. Nusinersen: a review in 5q spinal muscular atrophy. CNS Drugs. 2018;32(7):689\u201396.","journal-title":"CNS Drugs"},{"issue":"11","key":"3681_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"3681_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E, et al. Safety and treatment effects of Nusinersen in longstanding adult 5q-SMA type 3 - a prospective observational study. J Neuromuscul Dis. 2019;6(4):453\u201365.","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"3681_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R, Schreiber-Katz O, Osmanovic A, Petri S, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317\u201325.","journal-title":"Lancet Neurol"},{"key":"3681_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","volume":"27","author":"L Szab\u00f3","year":"2020","unstructured":"Szab\u00f3 L, Gergely A, Jakus R, Fogarasi A, Grosz Z, Moln\u00e1r MJ, et al. Efficacy of Nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from Hungarian patients. Eur J Paediatr Neurol. 2020;27:37\u201342.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"3681_CR21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","volume":"268","author":"B De Wel","year":"2021","unstructured":"De Wel B, Goosens V, Sobota A, Van Camp E, Geukens E, Van Kerschaver G, et al. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. J Neurol. 2021;268(3):923\u201335.","journal-title":"J Neurol"},{"key":"3681_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/00207454.2022.2095270","volume":"134","author":"Y Tachibana","year":"2024","unstructured":"Tachibana Y, Takasaki S, Hoshino M, Makioka H, Jin M. Real-world safety and effectiveness of Nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance. Int J Neurosci. 2024;134:153\u201362.","journal-title":"Int J Neurosci"},{"issue":"1","key":"3681_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti G, Cutrona C, Pera MC, Bovis F, Ponzano M, Chieppa F, et al. Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis. 2021;16(1):430.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3681_CR24","doi-asserted-by":"publisher","first-page":"e16309","DOI":"10.1111\/ene.16309","volume":"31","author":"G Coratti","year":"2024","unstructured":"Coratti G, Bovis F, Pera MC, Scoto M, Montes J, Pasternak A, et al. Determining minimal clinically important differences in the Hammersmith functional motor scale expanded for untreated spinal muscular atrophy patients: an international study. Eur J Neurol. 2024;31(8):e16309.","journal-title":"Eur J Neurol"},{"issue":"6","key":"3681_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.31083\/j.fbl2706179","volume":"27","author":"A Mirea","year":"2022","unstructured":"Mirea A, Leanca MC, Onose G, Sporea C, Padure L, Shelby ES, et al. Physical therapy and Nusinersen impact on spinal muscular atrophy rehabilitative outcome. Front Biosci (Landmark Ed). 2022;27(6):179.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"3","key":"3681_CR26","first-page":"CD012120","volume":"3","author":"B Bartels","year":"2019","unstructured":"Bartels B, Montes J, van der Pol WL, de Groot JF. Physical exercise training for type 3 spinal muscular atrophy. Cochrane Database Syst Rev. 2019;3(3):CD012120.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3681_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13023-021-01928-9","volume":"16","author":"T Nakajima","year":"2021","unstructured":"Nakajima T, Sankai Y, Takata S, Kobayashi Y, Ando Y, Nakagawa M, et al. Cybernic treatment with wearable cyborg hybrid assistive limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001). Orphanet J Rare Dis. 2021;16(1):304.","journal-title":"Orphanet J Rare Dis"},{"key":"3681_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-981-33-6280-2_11","volume-title":"Humans and devices in medical contexts: case studies from Japan","author":"T Nakajima","year":"2021","unstructured":"Nakajima T. Innovative technology, clinical trials and the subjective evaluation of patients: the cyborg-type robot HAL and the treatment of functional regeneration in patients with rare incurable neuromuscular diseases in Japan. In: Brucksch S, Sasaki K, editors. Humans and devices in medical contexts: case studies from Japan. Singapore: Springer Singapore; 2021. pp. 281\u2013310."},{"key":"3681_CR29","unstructured":"US Food and Drug Administration. HAL for medical use (lower limb type) 2020. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/devicesatfda\/index.cfm?db=pmn&id=K201559 Accessed August 16, 2024."},{"issue":"5","key":"3681_CR30","doi-asserted-by":"publisher","first-page":"720","DOI":"10.23736\/S1973-9087.21.06387-5","volume":"57","author":"M Kogawa","year":"2021","unstructured":"Kogawa M, Miura K, Yasuda K, Ishibashi Y, Tsuda E. Effect of gait training using hybrid assistive limb on gait ability and the risk for overwork weakness in the lower limb muscles in patients with neuromuscular disease: a proof-of-concept study. Eur J Phys Rehabil Med. 2021;57(5):720\u201330.","journal-title":"Eur J Phys Rehabil Med"},{"key":"3681_CR31","doi-asserted-by":"publisher","first-page":"905613","DOI":"10.3389\/fneur.2022.905613","volume":"13","author":"H Nakatsuji","year":"2022","unstructured":"Nakatsuji H, Ikeda T, Hashizume A, Katsuno M, Sobue G, Nakajima T. The combined efficacy of a two-year period of Cybernic treatment with a wearable cyborg hybrid-assistive limb and leuprorelin therapy in a patient with spinal and bulbar muscular atrophy: a case report. Front Neurol. 2022;13:905613.","journal-title":"Front Neurol"},{"issue":"9","key":"3681_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.braindev.2017.04.018","volume":"39","author":"K Kaneko","year":"2017","unstructured":"Kaneko K, Arakawa R, Urano M, Aoki R, Saito K. Relationships between long-term observations of motor milestones and genotype analysis results in childhood-onset Japanese spinal muscular atrophy patients. Brain Dev. 2017;39(9):763\u201373.","journal-title":"Brain Dev"},{"key":"3681_CR33","unstructured":"US Food and Drug Administration. Spinraza (nusinersen) injection, for intrathecal use: prescribing information. 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209531s013s014lbl.pdf Accessed August 16, 2024."},{"key":"3681_CR34","unstructured":"Cyberdyne. Guide to the proper use of HAL for medical, lower limb type [in Japanese]. 2016. Available from: https:\/\/www.cyberdyne.jp\/products\/pdf\/HT010911A-U01_R2.pdf Accessed August 16, 2024."},{"key":"3681_CR35","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Spinraza (nusinersen) intrathecal injection 12\u00a0mg: prescribing information [in Japanese]. 2022. Available from: https:\/\/www.pmda.go.jp\/drugs\/2022\/P20220307001\/630499000_22900AMX00587_A100_1.pdf Accessed August 16, 2024."},{"issue":"4","key":"3681_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","volume":"7","author":"M Main","year":"2003","unstructured":"Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7(4):155\u20139.","journal-title":"Eur J Paediatr Neurol"},{"issue":"9\u201310","key":"3681_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, et al. An expanded version of the Hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord. 2007;17(9\u201310):693\u20137.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"3681_CR38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55(6):869\u201374.","journal-title":"Muscle Nerve"},{"issue":"5","key":"3681_CR39","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1212\/WNL.0000000000002332","volume":"86","author":"LK Andersen","year":"2016","unstructured":"Andersen LK, Knak KL, Witting N, Vissing J. Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases. Neurology. 2016;86(5):442\u20135.","journal-title":"Neurology"},{"issue":"2","key":"3681_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nmd.2021.08.010","volume":"32","author":"KJ Krosschell","year":"2022","unstructured":"Krosschell KJ, Townsend EL, Kiefer M, Simeone SD, Zumpf K, Welty L, et al. Natural history of 10-meter walk\/run test performance in spinal muscular atrophy: a longitudinal analysis. Neuromuscul Disord. 2022;32(2):125\u201334.","journal-title":"Neuromuscul Disord"},{"key":"3681_CR41","first-page":"4209812","volume":"2020","author":"C de Baptista","year":"2020","unstructured":"de Baptista C, Vicente AM, Souza MA, Cardoso J, Ramalho VM, Mattiello-Sverzut AC. Methods of 10-Meter walk test and repercussions for reliability obtained in typically developing children. Rehabil Res Pract. 2020;2020:4209812.","journal-title":"Rehabil Res Pract"},{"issue":"1","key":"3681_CR42","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.1891\/1061-3749.24.1.44","volume":"24","author":"K Tanno","year":"2016","unstructured":"Tanno K, Bito S, Isobe Y, Takagi Y. Validation of a Japanese version of the decision regret scale. J Nurs Meas. 2016;24(1):E44\u201354.","journal-title":"J Nurs Meas"},{"key":"3681_CR43","doi-asserted-by":"publisher","first-page":"583574","DOI":"10.3389\/fpsyg.2020.583574","volume":"11","author":"RH Xu","year":"2020","unstructured":"Xu RH, Zhou LM, Wong EL, Wang D, Chang JH. Psychometric evaluation of the Chinese version of the decision regret scale. Front Psychol. 2020;11:583574.","journal-title":"Front Psychol"},{"key":"3681_CR44","unstructured":"O\u2019Connor AM. User Manual - Decision Regret Scale. 1996. Available from: https:\/\/decisionaid.ohri.ca\/docs\/develop\/User_Manuals\/UM_Regret_Scale.pdf Accessed August 16, 2024."},{"issue":"12","key":"3681_CR45","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1111\/ene.14472","volume":"27","author":"B Stolte","year":"2020","unstructured":"Stolte B, Bois JM, Bolz S, Kizina K, Totzeck A, Schlag M, et al. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy. Eur J Neurol. 2020;27(12):2586\u201394.","journal-title":"Eur J Neurol"},{"issue":"12","key":"3681_CR46","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1111\/ene.15542","volume":"29","author":"JF V\u00e1zquez-Costa","year":"2022","unstructured":"V\u00e1zquez-Costa JF, Povedano M, Nascimiento-Osorio AE, Moreno Escribano A, Kapetanovic Garcia S, Dominguez R, et al. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy. Eur J Neurol. 2022;29(12):3666\u201375.","journal-title":"Eur J Neurol"},{"issue":"5","key":"3681_CR47","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54(5):836\u201342.","journal-title":"Muscle Nerve"},{"issue":"4","key":"3681_CR48","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JND-200534","volume":"7","author":"VA Sansone","year":"2020","unstructured":"Sansone VA, Walter MC, Attarian S, Delstanche S, Mercuri E, Lochm\u00fcller H, et al. Measuring outcomes in adults with spinal muscular atrophy - Challenges and future directions - Meeting report. J Neuromuscul Dis. 2020;7(4):523\u201334.","journal-title":"J Neuromuscul Dis"},{"key":"3681_CR49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/1756-0500-7-269","volume":"7","author":"RW Bohannon","year":"2014","unstructured":"Bohannon RW, Bubela D, Magasi S, McCreath H, Wang YC, Reuben D, et al. Comparison of walking performance over the first 2 minutes and the full 6 minutes of the Six-Minute walk test. BMC Res Notes. 2014;7:269.","journal-title":"BMC Res Notes"},{"issue":"1","key":"3681_CR50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejpn.2018.10.001","volume":"23","author":"JW Witherspoon","year":"2019","unstructured":"Witherspoon JW, Vasavada R, Logaraj RH, Waite M, Collins J, Shieh C, et al. Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: is the 2-minute walk test an effective alternative to a 6-minute walk test? Eur J Paediatr Neurol. 2019;23(1):165\u201370.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"3681_CR51","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2340\/16501977-1916","volume":"47","author":"L Reid","year":"2015","unstructured":"Reid L, Thomson P, Besemann M, Dudek N. Going places: does the two-minute walk test predict the six-minute walk test in lower extremity amputees? J Rehabil Med. 2015;47(3):256\u201361.","journal-title":"J Rehabil Med"},{"key":"3681_CR52","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.lanepe.2024.100862","volume":"39","author":"R G\u00fcnther","year":"2024","unstructured":"G\u00fcnther R, Wurster CD, Brakemeier S, Osmanovic A, Schreiber-Katz O, Petri S, et al. Long-term efficacy and safety of Nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study. Lancet Reg Health Eur. 2024;39:100862.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"3681_CR53","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","volume":"15","author":"F Audic","year":"2020","unstructured":"Audic F, de la Banda MGG, Bernoux D, Ramirez-Garcia P, Durigneux J, Barnerias C, et al. Effects of Nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis. 2020;15(1):148.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3681_CR54","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.21686","volume":"187","author":"JE Mellerio","year":"2022","unstructured":"Mellerio JE. The challenges of clinical trials in rare diseases. Br J Dermatol. 2022;187(4):453\u20134.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3681_CR55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, et al. Safety and efficacy of once-daily Risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352.","journal-title":"Lancet Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03681-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03681-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03681-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:03:14Z","timestamp":1745413394000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03681-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3681"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03681-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for the publication of this manuscript was obtained from all participants of the analysis or their legal guardian. Consent was obtained according to the Declaration of Helsinki and within an appropriate ethical framework. The analysis protocol was approved by the ethics committee of the NHO Niigata National Hospital (approval number 211), NHO Osaka Toneyama Medical Centre (approval number TNH-2019002), and Kagoshima University Hospital (approval number 41\u2009\u2212\u20092).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent for publication was obtained from all participants of the analysis or their legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}